How many 8-K filings has Brainstorm Cell Therapeutics Inc. filed?

Brainstorm Cell Therapeutics Inc. (BCLI) has 30 8-K (Current Event Report) filings on record, spanning Apr 2024 to Nov 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Brainstorm Cell Therapeutics Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Brainstorm Cell Therapeutics Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Brainstorm Cell Therapeutics Inc. (BCLI) — 8-K Filings

All 8-K filings from Brainstorm Cell Therapeutics Inc.. Browse 30 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (30)

Brainstorm Cell Therapeutics Files 8-K — Nov 6, 2025 Risk: medium
On October 31, 2025, Brainstorm Cell Therapeutics Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity s
Brainstorm Cell Therapeutics Files 8-K — Aug 14, 2025 Risk: low
On August 14, 2025, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing indicates the company's financial condition and results of operations, wit
Brainstorm Cell Therapeutics Faces Delisting Concerns — Jul 17, 2025 Risk: high
Brainstorm Cell Therapeutics Inc. filed an 8-K on July 17, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The
Brainstorm Cell Therapeutics Files 8-K on Officer Changes & Shareholder Votes — Jun 25, 2025 Risk: medium
On June 25, 2025, Brainstorm Cell Therapeutics Inc. filed an 8-K report detailing several key events. The filing includes information regarding the departure of
Brainstorm Cell Therapeutics Files 8-K — Jun 16, 2025 Risk: low
On June 16, 2025, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," i
Brainstorm Cell Therapeutics Files 8-K — May 19, 2025 Risk: low
On May 19, 2025, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No
Brainstorm Cell Therapeutics Files 8-K — May 15, 2025 Risk: low
On May 15, 2025, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing pertains to the company's results of operations and financial condition, as w
Brainstorm Cell Therapeutics Files 8-K — Apr 21, 2025 Risk: low
Brainstorm Cell Therapeutics Inc. filed an 8-K on April 21, 2025, reporting on events as of April 20, 2025. The filing indicates amendments to its Articles of I
Brainstorm Cell Therapeutics Files 8-K with Key Agreements — Mar 31, 2025 Risk: medium
On March 31, 2025, Brainstorm Cell Therapeutics Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities.
Brainstorm Cell Therapeutics Updates Fiscal Year End — Mar 27, 2025 Risk: low
On March 25, 2025, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing indicates a change in the company's fiscal year end to December 31st. This
Brainstorm Cell Therapeutics Faces Delisting Concerns — Jan 21, 2025 Risk: high
Brainstorm Cell Therapeutics Inc. filed an 8-K on January 21, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company
Brainstorm Cell Therapeutics Faces Delisting Notice — Jan 15, 2025 Risk: high
On January 15, 2025, Brainstorm Cell Therapeutics Inc. filed an 8-K report indicating a notice of delisting or failure to satisfy a continued listing rule. The
Brainstorm Cell Therapeutics Files 8-K — Nov 14, 2024 Risk: low
On November 14, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial con
Brainstorm Cell Therapeutics Faces Delisting Concerns — Oct 30, 2024 Risk: high
Brainstorm Cell Therapeutics Inc. filed an 8-K on October 29, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company
Brainstorm Cell Therapeutics Files 8-K — Oct 1, 2024 Risk: low
On October 1, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing primarily serves as a notification of their financial statements and exhib
Brainstorm Cell Therapeutics Files 8-K — Sep 26, 2024 Risk: low
On September 26, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure, with no spe
Brainstorm Cell Therapeutics Files 8-K with Corporate Updates — Sep 16, 2024 Risk: medium
Brainstorm Cell Therapeutics Inc. filed an 8-K on September 16, 2024, reporting on several key events. These include the departure of a director, the election o
Brainstorm Cell Therapeutics Files 8-K on Financials — Aug 14, 2024 Risk: low
On August 14, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing pertains to the company's results of operations and financial condition, a
Brainstorm Cell Therapeutics Files 8-K on Shareholder Nominations — Jul 30, 2024 Risk: medium
On July 29, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report detailing shareholder nominations for its board of directors. This filing is related to
Brainstorm Cell Therapeutics Faces Delisting Notice — Jul 19, 2024 Risk: high
Brainstorm Cell Therapeutics Inc. filed an 8-K on July 18, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company, in
Brainstorm Cell Therapeutics Files 8-K with Key Agreements — Jun 28, 2024 Risk: medium
On June 27, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement,
Brainstorm Cell Therapeutics Files 8-K — Jun 26, 2024 Risk: low
On June 26, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific mater
Brainstorm Cell Therapeutics Files 8-K on Leadership Changes — Jun 20, 2024 Risk: medium
On June 19, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The filing also incl
Brainstorm Cell Therapeutics Faces Delisting Notice — Jun 4, 2024 Risk: high
Brainstorm Cell Therapeutics Inc. filed an 8-K on June 4, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is b
Brainstorm Cell Therapeutics Faces Delisting Concerns — May 3, 2024 Risk: high
Brainstorm Cell Therapeutics Inc. filed an 8-K on May 1, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is ba
Brainstorm Cell Therapeutics Announces Board Changes and New CMO — Apr 17, 2024 Risk: medium
On April 16, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, incl
Brainstorm Cell Therapeutics CFO Resigns, Interim Appointed — Apr 11, 2024 Risk: medium
On April 10, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report detailing the resignation of its Chief Financial Officer, Dr. Arthur S. Tisch. The comp
Brainstorm Cell Therapeutics Files 8-K — Apr 9, 2024 Risk: low
On April 9, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific mater
Brainstorm Cell Therapeutics Files 8-K — Apr 2, 2024 Risk: medium
On April 2, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements
Brainstorm Cell Therapeutics Files 8-K on Financials — Apr 1, 2024 Risk: low
On April 1, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial conditi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX